Currently out of the existing stock ratings of Andrew Berens, 169 are a BUY (69.26%), 56 are a HOLD (22.95%), 19 are a SELL (7.79%).

Andrew Berens

Work Performance Price Targets & Ratings Chart

Analyst Andrew Berens, carries an average stock price target met ratio of 58.37% that have a potential upside of 33.37% achieved within 235 days. Previously, Andrew Berens worked at LEERINK.

Andrew Berens’s has documented 481 price targets and ratings displayed on 39 stocks. The coverage was on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on AGIO, Agios Pharm at 26-Dec-2025.

Wall Street Analyst Andrew Berens

Analyst best performing recommendations are on ELEV (ELEVATION ONCOLOGY).
The best stock recommendation documented was for ELEV (ELEVATION ONCOLOGY) at 1/9/2023. The price target of $1 was fulfilled within 3 days with a profit of $0.2 (25%) receiving and performance score of 83.33.

Average potential price target upside

of $98.9 (13.22%) on REGN (REGENERON PHARMACEUTICALS).
of $43.61 (23.29%) on BGNE (BEIGENE LTD).
of $35.58 (28.6%) on GWPH (GW PHARMACEUTICALS PLC).

AGIO Agios Pharm AVEO AVEO Pharmaceuticals BGNE BeiGene Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EPZM Epizyme FMTX Forma Therapeutics Holdings GPRE Green Plains Renewable Energy INCY yte MRTX Mirati Ther SGEN Seagen ZNTL Zentalis Pharmaceuticals Llc ZYME Zymeworks Common Stock AZN AstraZeneca PLC ADR CLVS Clovis Oncology GILD Gilead Sciences GWPH GW Pharmaceuticals plc HOOK Hookipa Pharma ARVN Arvinas GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals MRUS Merus BV OCUL Ocular Therapeutix RLYP Relypsa CGEM Cullinan Oncology LLC CMPX Compass Therapeutics GLUE Monte Rosa Therapeutics TNGX Tango Therapeutics TPTX Turning Point Therapeutics NRIX Nurix Therapeutics COGT Cogent Biosciences ELEV Elevation Oncology AURA Aura Biosciences RMTI Rockwell Medical THRX Theseus Pharmaceuticals CTIC CTi Biopharma Corp REGN Regeneron Pharmaceuticals VIRX Viracta Therapeutics NUVL Nuvalent

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score